Get the Stockscreener App
10.13
3.62%
-0.38
After Hours:
10.12
-0.01
-0.10%
Intellia Therapeutics Inc Stock (NTLA) Latest News
Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025 - Insider Monkey
First HAE patient dosed in Phase 3 trial of NTLA-2002 gene therapy - Angioedema News Today
Q1 EPS Estimate for Intellia Therapeutics Lifted by Analyst - MarketBeat
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia downgraded at Morgan Stanley on lowered expectations for rare disease asset - MSN
Intellia's Latest Executive Compensation Package Reveals Growth Strategy - StockTitan
Angioedema Pipeline 2024: Therapies Under Investigation, - openPR
Lewis Asset Management LLC Sells 25,313 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 7.1%Time to Sell? - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
How Is The Market Feeling About Intellia Therapeutics? - Benzinga
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, IncNTLA - Kilgore News Herald
Goldman Sachs Slashes Intellia Therapeutics Price Target to $12 Per Share from $19 – Market - HPBL
2025-01-28 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Shareholders to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
Intellia Therapeutics (NASDAQ:NTLA) Downgraded to “Equal Weight” Rating by Morgan Stanley - Defense World
Morgan Stanley Downgrades Intellia Therapeutics (NTLA) - MSN
Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade -January 27, 2025 at 03:03 pm EST - Marketscreener.com
Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56 - Marketscreener.com
Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Trading (NTLA) With Integrated Risk Controls - Stock Traders Daily
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan Stanley - MarketBeat
This RingCentral Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Morgan Stanley cuts Intellia stock rating amid gene editing concerns - MSN
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Shareholders to Inquire about Securities Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 9%Time to Buy? - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Trading 9% HigherStill a Buy? - MarketBeat
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate - Yahoo Finance
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema - Clinical Trials Arena
Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive
Intellia Therapeutics Announces First Patient Dosed in the - GlobeNewswire
Intellia Doses First Patient in Phase 3 CRISPR Gene Editing Trial for Hereditary Angioedema - StockTitan
Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Investors to Learn More About the Investigation - Markets Insider
2025-01-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Investors to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
2025-01-20 | Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
Avanza Fonder AB Purchases Shares of 36,065 Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year LowHere's What Happened - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Hennion & Walsh Asset Management Inc. - MarketBeat
Intellia Loses 21.6% in a Week: How Should You Play the Stock? - MSN
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential (NASDAQ:EDIT) - Seeking Alpha
Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowTime to Sell? - MarketBeat
2025-01-17 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):